Exosome and Microvesicle-Enriched Fractions Isolated from Mesenchymal Stem Cells by Gradient Separation Showed Different Molecular Signatures and Functions on Renal Tubular Epithelial Cells

Federica Collino¹² · Margherita Pomatto² · Stefania Bruno³ · Rafael Soares Lindoso¹ · Marta Tapparo² · Wen Sicheng⁴ · Peter Quesenberry⁴ · Giovanni Camussi²

Abstract Several studies have suggested that extracellular vesicles (EVs) released from mesenchymal stem cells (MSCs) may mediate MSC paracrine action on kidney regeneration. This activity has been, at least in part, ascribed to the transfer of proteins/transcription factors and different RNA species. Information on the RNA/protein content of different MSC EV subpopulations and the correlation with their biological activity is currently incomplete. The aim of this study was to evaluate the molecular composition and the functional properties on renal target cells of MSC EV sub-populations separated by gradient floatation. The results demonstrated heterogeneity in quantity and composition of MSC EVs. Two peaks of diameter were observed (90–110 and 170–190 nm). The distribution of exosomal markers and miRNAs evaluated in the twelve gradient fractions showed an enrichment in fractions with a flotation density of 1.08–1.14 g/mL. Based on this observation, we evaluated the biological activity on renal cell proliferation and apoptosis resistance of low (CF1), medium (CF2) and high (CF3) floatation density fractions. EVs derived from all fractions, were internalized by renal cells, CF1 and CF2 but not CF3 fraction stimulated significant cell proliferation. CF2 also inhibited apoptosis on renal tubular cells submitted to ischemia-reperfusion injury. Comparative miRNomic and proteomic profiles reveal a cluster of miRNAs and proteins common to all three fractions and an enrichment of selected molecules related to renal regeneration in CF2 fraction. In conclusion, the CF2 fraction enriched in exosomal markers was the most active on renal tubular cell proliferation and protection from apoptosis.

Keywords Extracellular vesicles · Mesenchymal stem cells · Exosomes · Microvesicles · Acute kidney injury · Kidney regeneration

Introduction

Extracellular vesicles (EVs) are small extracellular membrane fragments heterogeneous for their origin, dimensions and content. EVs are mainly composed by exosomes, small homogeneous vesicles (50–150 nm) formed from the endosomal cell compartment, and by microvesicles, with a more heterogeneous dimension profile, produced by the direct extrusion of the cell plasma membrane. Ratajczak et al. [1] first demonstrated that embryonic stem cells may release EVs capable to reprogram hematopoietic progenitors. EVs derived from adult stem/progenitor cells have been described to retain features resembling their cells of origin. In particular, EVs derived from mesenchymal stem cells (MSCs) can mediate the paracrine effects of MSCs in different models of tissue regeneration [2–5]. Selective molecules such as proteins, RNAs and...
small non coding RNAs are compartmentalized inside EVs [1, 6–10], and may be transferred to target cells via EVs. Numerous studies reported the heterogeneity in EV populations. Exosomes showed the presence of subsets of cellular proteins, such as the tetraspanin family members (CD63, CD81 and CD9), heat-shock proteins [11], and endosomal sorting complexes proteins, such as Alix and TSG101 [12]. Moreover, specific subsets of small RNAs have been described as selectively incorporated in different EV populations [13, 14]. Functional studies have been usually performed using a heterogeneous EV combination or selective sub-fractions [15, 16]. Numerous protocols to isolate EV sub-populations have been described [17], but to identify a method to separate a pure population still remains challenging [18]. EVs from MSCs (MSC EVs) have been extensively used for the treatment of acute kidney injury (AKI), showing regenerative properties. These were ascribed, at least in part, to the transfer of RNA species, such as mRNAs and miRNAs [2, 8, 10], and may be transferred to target cells via EVs. Numerous studies reported the heterogeneity in EV populations. Exosomes showed the presence of subsets of cellular proteins, such as the tetraspanin family members (CD63, CD81 and CD9), heat-shock proteins [11], and endosomal sorting complexes proteins, such as Alix and TSG101 [12]. Moreover, specific subsets of small RNAs have been described as selectively incorporated in different EV populations [13, 14]. Functional studies have been usually performed using a heterogeneous EV combination or selective sub-fractions [15, 16]. Numerous protocols to isolate EV sub-populations have been described [17], but to identify a method to separate a pure population still remains challenging [18]. EVs from MSCs (MSC EVs) have been extensively used for the treatment of acute kidney injury (AKI), showing regenerative properties. These were ascribed, at least in part, to the transfer of RNA species, such as mRNAs and miRNAs [2, 8, 19, 20]. Comprehensive information on the RNA/protein content of different subpopulation of MSC EVs is currently incomplete.

The aim of this study was to analyze the composition and activity of different EV sub-populations released from MSCs, defining the molecular profile associated with their activity on renal tubular epithelial cells. For this purpose, we fractioned by density gradient the conditioned medium (CM) of MSCs and investigated the different EV subpopulations obtained. Moreover, we combined different gradient fractions (CFs), on the bases of differential expression of exosomal markers and density, and then we characterized their biological activity on renal target cells. The signaling pathway (s) associated with the protein and miRNA cargo content of different EV subpopulations have also been investigated in relation with their biological activity.

Materials and Methods

Cell Culture

Bone marrow MSCs were purchased by Lonza (Basel, Switzerland) and cultured as previously described [2]. Cells were used within the seven passages. MSCs characterization was performed by cytofluorimetric analysis for the expression of the typical mesenchymal markers as described [2]. Murine tubular epithelial cells (mTEC) were isolated from the kidneys of healthy C57 mice. Cells were cultured and characterized as previously described by Bruno et al. [2]. mTEC were positive for classical epithelial markers such as: cytokeratin, actin, alkaline phosphatase, aminopeptidase A, and megalin, and negative for CD45, von Willebrand factor, desmin and nephrin.

Preparation of Extracellular Vesicles-Containing Conditioned Medium

For the preparation of the conditioned medium (CM), MSCs (passage 3–7) were cultured in the presence of their expansion medium until 80% of confluence. Conditioned medium was obtained from supernatants of 8.95 ± 0.46 × 10^3/cm^2 MSCs maintained in RPMI medium supplemented with 0.1% BSA for 16 h. The viability of MSCs after starvation was about 86 ± 0.5% as detected by the Muse Count & Viability Assay Kit (CTRL normal medium 88.9% of vitality) (Millipore, MA, USA). Supernatant was first centrifuged at 1500 g for 20 min, to remove debris and apoptotic bodies and then concentrated at 4 °C, approximately 200-fold, using ultrafiltration units (Amicon Ultra-PL 3, Millipore) with a 3 kDa molecular weight cut-off as previous described [21]. After the concentration CM-containing EVs in 1% dimethyl sulfoxide was kept at −80 °C until use.

Density Gradient Separation of EVs

A discontinuous iodixanol gradient was prepared as described by Tauro et al. [22]. Solutions of 5, 10, 20 and 40% iodixanol were obtained by mixing an OptiPrepTM (60% w/v aqueous iodixanol solution) (Sigma-Aldrich, St. Louis, MO) with the appropriate amounts of homogenization buffer (0.25 M sucrose/ 10 mM EDTA/ 10 mMTris-HCL, pH 7.4). The gradient was formed by layering 3 ml of 40%, 3 ml of 20%, 3 ml of 10% and 2.5 ml of 5% solutions in a 13 ml open top polycarbonate tube (Beckman Coulter). 500 μl of CM-containing EVs (cCM-EVs) were overlaid onto the top of the gradient [22] or at the bottom [23] and centrifuged for 18 h at 100,000 g at 4 °C (SW 40 Ti rotor, Beckman Coulter Optima L-90 K ultracentrifuge, Indianapolis, IN). Preliminary experiments demonstrated the same vesicles distribution using the protocols listened above (not shown) and the loading from the top of the gradient [22] was used in the following experiments.

Twelve gradient fractions of 1 ml, were collected from the top of the gradient, diluted with 10 ml PBS for washing and centrifuged at 100,000 g for 2 h at 4 °C. The pellets were resuspended in 100 μl PBS or medium based on the following use. The density of each fraction was measured by weighing a fixed volume [16]. In some experiments, fractions were divided into three groups (combined fractions, CFs), based on their density and on the expression of specific surface markers (Fractions 1–4 low density, CF1; Fractions 5–8, medium density CF2; Fractions 9–12, high density CF3).

EV Incorporation

To trace EVs by fluorescence microscopy, MSCs were labeled with Vybrant Cell Tracers Dil and Syto-RNA (Life
Technologies, Carlsbad, CA) as previous described [20]. EVs obtained from labeled cells were concentrated and subjected to gradient separation as described above. For EV incorporation, mTEC were plated in 24-well plated and treated with different doses of labeled cCM-EVs (50,000, 150,000, 300,000 or 600,000 EVs/cell) for 24 h. Quantitative analysis of the EV uptake was conducted by FACS. To determine the incorporation of each fraction, mTEC were seeded into 24-well plates and incubated with labeled EVs (150,000 EVs/cell) from the different combined fractions for 24 h. The uptake of EVs was analyzed by microscope analysis using the ApoTome system (Carl Zeiss, Oberkochen, Germany). Hoechst 33,258 dye (Sigma-Aldrich) was added for nuclear staining.

**In Vitro Models**

mTEC were seeded at 1500 cells/well into 96-well plates and cultured in serum free low-glucose DMEM in the absence (vehicle, CTR-) or presence of EVs (1 × 10^7 EVs/ml, 1 × 10^8 EVs/ml or 1 × 10^9 EVs/ml). Cells maintained in low-glucose DMEM (Sigma-Aldrich) plus 10% FCS were used as positive control (CTR+). In selected experiments, to mimic the ischemia damage on renal cells, mTEC cultured in serum free DMEM were placed in hypoxic chambers with 1% O_2 for 48 h. The re-oxygenation step was conducted for 24 h, in the absence (vehicle, HY/CTR-) or presence of EVs (1 × 10^7 EVs/ml), DMEM plus 10% FCS (HY/CTR+) or EGF (10 ng/ml, Sigma) (HY/EGF) in the re-oxygenation step were used as controls. For cell proliferation, DNA synthesis was detected as incorporation of 5-bromo-2′-deoxy-uridine (BrdU) into the cellular DNA at 48 h (Roche Applied Science, Mannheim, Germany). Apoptosis/necrosis was measured by Muse™ Caspase-3/7 Kit (Millipore) following the instructions. Percentage for live, apoptotic, and necrotic cells was measured.

**EV Characterization**

Gradient isolated EVs were analyzed by nanoparticle tracking analysis (NTA), using the NanoSight LM10 system (NanoSight Ltd., Amesbury, UK), equipped with a 405 nm laser and with the NTA 2.3 analytic software, to define their dimension and profile. Camera levels were for all the acquisition at 16 and for each sample, five videos of 30 s duration were recorded. Briefly, cCM-EVs or gradient-separated EVs were diluted (1: 1000 and 1: 10, respectively) in 1 ml vesicle-free physiologic solution (Fresenius Kabi, Runcorn, UK). NTA post-acquisition settings were optimized and maintained constant among fractions, and each video was then analyzed to measure EV mean, distribution and concentration.

EVs from the twelve fractions were characterized by cytofluorimetric analysis using the Guava easyCyte Flow Cytometer (Millipore) with InCyte software. The following FITC or APC conjugated antibodies were used: CD107, CD81 and CD63. FITC or APC mouse non-immune isotypic IgG (Miltenyi Biotec, Bergisch Gladbach, Germany) were used as controls as previously described [20]. Briefly, immediately after labelling for 15 min at 4 °C with antibodies, EVs (1.5 × 10^8 particles) diluted 1 to 3 were acquired.

**Western Blot Analysis**

For protein analysis, EVs from different fractions and MSCs were lysed at 4 °C for 30 min in RIPA buffer (20 nM Tris-HCl, 150 mM NaCl, 1% deoxycholate, 0.1% SDS, 1% Triton X-100, pH 7.8) supplemented with protease and phosphatase inhibitors cocktail (Sigma-Aldrich). Protein content in EV fractions were quantified by BCA Protein Assay Kit (Pierce, Thermo Fisher Scientific, Waltham, MA). Ten μg of proteins were then separated by 4% to 15% gradient sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The proteins were transferred onto a PVDF membrane by the iBlot™ Dry Blotting System (Life Technology) and then immunoblotted with the following antibodies: CD63 and ANXA2 (Santa Cruz Biotechnology, Santa Cruz CA), HLA1 (Abcam, Cambridge, United Kingdom), CD29 (Thermo Fisher Scientific) and Integrin alpha-5 (Millipore). The protein bands were visualized using a ChemiDoc™ XRS + (BioRad) with an enhanced chemiluminescence detection kit (ECL) (GE healthcare, Amersham, Buckinghamshire, UK).

**Electron Microscopy**

Transmission electron microscopy of EVs was performed by loading EVs from different CF onto 200 mesh nickel formvar carbon coated grids (Electron Microscopy Science, Hatfield, PA) for 20 min. EVs were then fixed with a solution containing 2.5% glutaraldehyde and 2% sucrose and after repeated washings in distilled water, samples were negatively stained with NanoVan (Nanoprobes, Yaphank, NK, USA) and examined by Jeol JEM 1010 electron microscope.

**RNA Isolation**

Total RNA was isolated from gradient separated EVs using the mirVana RNA isolation kit (Applied Biosystem) according to the manufacturer’s protocol. RNA from all the twelve fractions or from the three CFs was quantified (Nanodrop ND-1000, Wilmington DE) and the small RNA composition of different CFs was assessed by capillary electrophoresis on an Agilent 2100 Bioanalyzer using the small RNAs kit (Agilent Technologies, Inc., Santa Clara, CA).
miRNA Screening

Purified CF-derived EVs isolated from three different MSCs preparations were analyzed for their miRNA content by quantitative real time (qRT) PCR using the Applied Biosystems TaqManH MicroRNA Assay Human Panel Early Access kit (Life Technologies), able to profile 754 human mature miRNAs by sequential steps of reverse transcription (Megaplex RT Pools; Life Technologies) using an Applied Biosystems 7900H qRT-PCR instrument as previously described [20]. Briefly, single stranded cDNA was generated from total RNA sample (80 ng) by reverse transcription using a mixture of looped primers (Megaplex RT kit, Life Technologies) following manufacturer’s protocol. The pre-amplification reaction for each sample was performed using a TaqMan® PreAmp Master Mix 2X (Life Technologies) mixed with specific Megaplex™ PreAmp Primers (10X) (Life Technologies). Pre-amplified products were then diluted, loaded in the TaqMan MicroRNA Array and qRT-PCR experiments were performed.

Raw Ct values, automatic baseline and threshold were calculated using the SDS software version 2.3. Comparison of miRNA expression was conducted using the Expression Suite software (Life Technologies). Fold change (Rq) in miRNA expression among the three fractions was calculated as 2-ΔΔCt using one of the fraction (CF2) as control and normalizing the data using global normalization [24]. Confirmation of the expression of specific miRNAs in the three fractions was conducted using the miScript SYBR Green PCR Kit (Qiagen, Valencia, CA, USA). Briefly, 50 ng of input RNA were reverse transcribed using the miScript Reverse Transcription Kit and the cDNA was then used to detect and quantify miRNAs of interest. Experiments were run in triplicate using 3 ng of cDNA for each reaction as described by the manufacturer’s protocol (Qiagen). The following miRNAs were screened in all the CF: miR-100, miR-21, miR-24, miR-214, miR-34a, miR-127, miR-30c, miR-29a, miR-125b, miR-10b, let-7c, miR-99a, miR-17 and miR-20a.

Analysis of miR-451 distribution in the twelve fractions was carried on using the miCURY LNA™ Universal RT microRNA PCR kit (Exiqon, A/S, Vedbaek, Denmark). Fifty pg of reverse transcription reaction products were then combined with SYBR Green Master Mix (Exiqon) and LNA™ PCR primer mix and analyzed as described by the manufacturer’s protocol. All the qRT-PCR data were normalized using the UniSp6 and the UniSp2 RNA Spike-in templates respectively as cDNA synthesis and RNA extraction controls (Exiqon).

Protein Array

Purified CF-derived EVs isolated from different MSC preparations were lysed in 2× Cell Lysis Buffer (RayBiotech, Inc., GA), and 15 μg of EV proteins from all the CFs, were used for RayBio Label-based (L-Series) Human Antibody Array 1000 (RayBiotech) according to the manufacturer instructions. The arrays were performed in duplicates, using a pull of EVs derived from two different MSC preparations/array. The array provides detection of 1000 proteins.

Data analysis was conducted after background signal subtraction and normalization to positive controls (Mean background +4 standard deviations, accuracy ≈ 99%). Comparison of signal intensities among array images was used to define relative differences in expression levels of each protein among the CF fractions. Differential expression analysis was conducted using CF2 as reference fraction. Proteins were considered co-expressed when they showed a Fold change (FC) = 0.65 ≤ FC ≤ 1.5 in all sample tested. Differential expression among CFs was considered when FC distribution: <0.65 or >1.5 in all the sample tested.

Pathway and Gene Ontology Analysis of EV Content

For CF2 miRNA target prediction and biological pathway enrichment analysis, the web-based program DIANA-mirPath [25] was used. The algorithm microT-CDS was chosen to predict EV-derived miRNA targets using default threshold (microT = 0.8). Only biological pathways showing P value < 0.01 to all known Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were considered as significantly enriched.

For protein class analysis and pathway classification Panther classification system was used (http://pantherdb.org/). Gene Ontology (GO) analysis was conducted using David functional annotation tool (http://david-d.ncifcrf.gov/). Functional sorting of the proteins differentially expressed between CF2 and the other fractions was done using Funrich analysis tool [26].

Statistical Analysis

Data were analyzed using the GraphPad Prism 6.0 Demo program. Statistical analyses were conducted using One-way ANOVA with Dunnett’s or Turkey’s post-tests, where appropriated. Statistical significance was established at P < 0.05.

Results

Heterogeneity of EVs Released from MSCs.

To isolate a total EV population from MSCs, we pre-purified their CM as described in Material and Methods. The CM was then subjected to concentration and the number of isolated EVs was counted by NTA. We observed that the mean number
of EVs present in the concentrated CM was around 12,750 ± 3187 particles/cell. The cCM-EVs represented a mix population with different diameter, ranging from 50 to 390 nm (Fig. 1a). Two peaks of diameter were defined around 90–110 and 170–190 nm (Fig. 1a) with a mean diameter in the total population of 136 ± 16 nm and a mode of 119 ± 21 nm. The identification of a heterogeneous population prompts us to define its molecular content and activity. For this purpose, we fractionated the cCM-EVs by density gradient separation, isolating twelve different EV fractions. Density of each fraction was measured by weighing a fixed volume (Fig. 1b) [16]. The analysis of EV distribution by NTA, showed an enrichment of vesicles in fractions 1, 4 and 8 (Fig. 1c).

Characterization of EVs in Different Fractions.

By FACS analysis the expression of CD63 endosome-derived exosome marker was mainly observed in fractions 5–8, with a flotation density of 1.08–1.14 g/mL (Fig. 2a). The other tetraspanin family member, CD81 and the lysosomal-associated membrane protein 1, CD107, showed almost the same sinusoidal pattern (Fig. 2a). As shown in Fig. 2b, the biological activity on mTEC is widely distributed in different fractions, except for the densest fractions, but is significantly higher in fraction 6.

Total RNA was extracted from all the twelve fractions and the major concentration of RNA was isolated from fractions 5, 8, 9 and 11 (not shown). Since it has been suggested a selective export of specific miRNAs from different cell compartments [10], we evaluated the distribution of a group of miRNAs that we previously described in MSC-derived EVs [8]. miR-21 was expressed in almost all the EV fractions. However, as shown in Fig. 2c, the Raw Ct of miR-21 indicated its enrichment in the central fractions (Fig. 2c). Similar enrichment pattern was observed for miR-100, −99a and −24 (data not shown). Conversely, miR-451 was detected only in central fractions enriched in the tetraspanin family markers (Fig. 2C) and this distribution was compatible with the exosomal derivation of this miRNA. To exclude the possibility of confounding technical factors on the obtained results, we performed miR-451 quantification adding a synthetic spike-in (UniSp6) during the cDNA synthesis. We obtained the same results, demonstrating the effective compartmentalization of miR-451 mainly in the CD63 positive fractions (Fig. 2d).

Biological Effect and Characterization of EV Combined Fractions

In order to pair the biological activity with the molecular content of the EV subpopulations, we combined the gradient fractions into three groups (Fractions 1–4, low density CF1; Fractions 5–8, medium density CF2; Fractions 9–12, high density CF3), based on their density and on the expression of exosome surface markers and miRNAs. We first analyzed the up-take of labelled cCM-EVs by mTEC. Figure 3a shows a dose dependent up-take of cCM-EVs. We then tested the uptake of EVs from the different fractions using confocal microscopy (Fig. 3b-d). Using EVs labelled with Vybrant Dil and with Syto-RNA, we observed the concomitant presence within the cells of the two dyes, suggesting the EV delivery of RNAs inside mTEC.

To discriminate the effects of the different EV fractions on cell proliferation and apoptosis, in vitro experiments were performed. Despite all EV fractions slightly promoted cell proliferation on mTEC, only the low density CF1 and medium density CF2 fractions induced a statistically significant
proliferation at $1 \times 10^8$ and $1 \times 10^9$ particles/ml concentration (Fig. 3e). We next evaluated the effects of the combined fractions in a hypoxia/reperfusion model that mimics renal tubule damage during the ischemia reperfusion injury (IRI). For this purpose, mTEC were treated with CFs during the re- oxygenation phase of IRI. Only the CF2 medium-density vesicles together with the EGF treatment during the reperfusion phase were anti-apoptotic (Fig. 3f). On the contrary, CF1 low-density vesicles or CF3 high density EVs were not significantly protective on mTEC submitted to IRI.

To define the molecular composition of the EV gradient fractions, accountable for their different biological potential, further characterization studies were conducted. Transmission electron microscopy analysis performed on purified EVs showed their spheroid morphology (Fig. 4a). The size of EVs present in CF1 was more heterogeneous of the CF2 ones. NTA quantification of the particle distribution among the CF demonstrated an enrichment of vesicles in CF1 and CF2 in respect to CF3 fraction (Fig. 4b). As shown in Fig. 4c, NTA measure of the percentage of size distribution indicated that...
CF1 and CF2 contain smaller EVs (50–150 nm) whereas the CF3 is also enriched in EVs of larger size (>200 nm). The mean diameter of the different populations was respectively: 134.7 ± 19.7 for CF1, 147 ± 27.5 for CF2 and 169 ± 39 for CF3 (Fig. 4c, lower panel).

The expression of some classical vesicular markers (CD63, ANXA2 and CD29) was compared among the three CFs and their cells of origin by Western blot analysis (Fig. 4d-e). The integrin alpha-5 and HLA-1 were also screened in the different fractions (Fig. 4e). CD63 was almost absent in low-density vesicles of CF1, being enriched in the medium-density EVs of CF2 fraction and into a lesser extent in the high-density CF3 fraction (Fig. 4d). The integrin beta-1 (CD29), showed the same distribution of the tetraspanin CD63, being enriched in CF2 and CF3 and expressed at low levels in CF1 fraction (Fig. 4e). ANXA2, involved in recruitment of miRNAs in EVs, resulted mainly present in fraction CF2 and CF3 (Fig. 4e), supporting the relevant enrichment of miRNAs detected in these two fractions (Fig. 4f). The HLA-class I and alpha-5 integrin (ITGA5) were selectively expressed by the medium-density fraction CF2 (exosome enriched fraction) and almost absent in CF1 low-density fraction (Fig. 4e). Low expression of these two markers was observed in the CF3 high-density fraction (microvesicle enriched fraction).

miRNA Compartmentalization inside CF Fractions

RNA was extracted by different CFs and spectrometrically quantified. The bioanalyzer profile showed the enrichment of RNA of the size of miRNAs in the medium-density CF2 and high-density CF3 fractions (Fig. 4f). No relevant differences in the total RNA isolated in respect to the EV quantity among the three CFs was observed (CF1: 2.62 ± 0.97, CF2: 2.75 ± 0.78, CF3: 2.94 ± 0.88 × 10^-9 ng/particle) (Fig. 5a).

The expression of 754 human miRNAs was measured by qRT-PCR. Analyzing the normalized Cycle threshold distribution (ΔCt, based on Median calculation) of all expressed miRNAs (Ct < 40), the medium-density EVs of CF2 fraction showed a low correlation with both CF3 and CF1 EV populations (Pearson correlation: 0.50 and 0.69, respectively) (Fig. 5b).
Using a cut-off \( \leq 35 \) Ct value in miRNA expression, we found 162 miRNAs present in all the EV fractions (Fig. 5c; Table 1). The analysis showed a selective package of miRNA subsets in medium-density CF2 EV fraction which were undetected in the other fractions (Table 2) (Fig. 5c). Among these miRNAs, we observed 19 miRNA* sequences detected only in the CF2 fraction, as previously described for tumor derived exosome population [14].

By analyzing the fold change distribution of the co-expressed miRNAs among all the fractions (miRNA intersection), we observed a relevant enrichment of miRNAs in CF2 fraction containing exosome enriched-EVs. Among the 162 miRNAs expressed by all the fractions, we found that 112 miRNAs were significantly up-regulated in the CF2 fraction in respect to CF1 (Fig. 5d) and only 12 miRNAs were down-regulated. The same trend was observed between CF2 and CF3 (89 miRNAs up-regulated and 15 down-regulated in CF2 in respect to CF3) (Fig. 5c).

In CF2, we detected 106 miRNA families with an enrichment of the following families: miR-10, miR-17, miR-154, miR-30, miR-27, miR-15, let-7, miR-379, miR-26, miR-34 and miR-548 families (not shown).

We confirmed by qRT-PCR the compartmentalization of miRNAs highly enriched in MSC EVs and/or connected with kidney regeneration in the CF2 fraction (miR-100, –21, –24, –214, –34a, –127, –30c, –29a, –125b, –10b, –let-7c, –99a, –17 and let-7c) [8, 27–32] (Fig. 5f). Some miRNAs, such as miR-21, –24, –214, and –17 were also enriched in the dense fraction CF3, possibly being a common signature of different EV sub-fractions. Reduced miRNA content was detected in the low-density EV CF1 fraction (Fig. 5f).

Analysis of the pathways over-represented by the predicted targets of enriched/selective CF2 miRNAs was performed with the DIANA mirPath software, as previously described [33]. We detected an enrichment of 14 KEGG biological processes for the CF2 enriched miRNAs and 11 KEGG processes for the CF2 selective miRNAs (P < 0.01, FDR corrected) (S1 Table and S2 Table). Sixty-nine miRNAs from the two groups showed strong correlation with the same pathways assembled in metabolic, stem cell associated- and migration/inflammation processes.

The following metabolic-related pathways were over-represented: fatty acid biosynthesis and metabolism, biosynthesis of unsaturated fatty acids, mucin type O-glycan biosynthesis.
and lysine degradation (Table 3). Pathways related to stem cells were: Hippo signaling, Wnt signaling and pluripotent stem cells regulated-pathways (Table 3). Migration-inflammation related processes such as ECM-receptor interaction, TGF-β signaling pathway, glioma and proteoglycans in cancer were also over-represented (Table 3). Heatmap representation of the most significantly enriched pathways potentially modulated by the 69 miRNAs is shown in Fig. 6.

Protein Characterization in CF Fractions.

Protein composition of different CFs could also define their origin and activity. For this reason, proteins were isolated from the three CFs and quantitative proteomic analysis of 1000 proteins was then conducted. Raw data was reported as supplementary information (S3 Table). We observed first a different distribution of total proteins among the three fractions with an enrichment of isolated proteins in respect to the EV quantity in CF3 high-density fraction (Fig. 7a). Less amount of proteins was isolated in CF1 in respect to the high quantity of EVs detected in this fraction.

Proteomic profile of all CFs showed the presence of 655 proteins in the CF2 fraction over the 1000 analyzed. 435 proteins were compartmentalized in the CF3 high-density fraction and 581 in the CF1 low-density fraction. A group of 413 proteins was detected in all the EV populations. Panther
Table 1  List of the miRNAs detected in all the CF fractions. The miRNAs confirmed by qRT-PCR were labeled in red

| List of miRNAs present in all the CFs |
|---------------------------------------|
| hsa-miR-1243  | hsa-miR-20a  | hsa-miR-15b  | hsa-miR-323-3p |
| hsa-miR-15a  | hsa-miR-886-5p | hsa-miR-27b  | hsa-miR-532-3p |
| hsa-miR-1274B | hsa-miR-376c  | hsa-miR-25   | hsa-miR-29b   |
| hsa-miR-302c | hsa-miR-92a  | hsa-miR-218  | hsa-miR-214#  |
| hsa-miR-1274A | hsa-miR-106b  | hsa-miR-766  | hsa-miR-151-3p|
| hsa-miR-720  | hsa-miR-30c-3p | hsa-miR-34a  | hsa-miR-320B  |
| hsa-miR-24   | hsa-miR-26a  | hsa-miR-532  | hsa-miR-324-3p|
| hsa-miR-99a  | hsa-miR-152  | hsa-miR-625# | hsa-miR-125b-l|
| hsa-miR-100  | hsa-miR-1260 | hsa-let-7g   | hsa-miR-410   |
| hsa-miR-19b  | hsa-miR-31#  | hsa-miR-539  | hsa-miR-629   |
| hsa-miR-125b | hsa-miR-382  | hsa-miR-133a | hsa-miR-126#  |
| hsa-miR-367  | hsa-miR-335  | hsa-miR-146a | hsa-miR-571   |
| hsa-miR-191  | hsa-miR-365  | hsa-miR-345  | hsa-miR-142-3p|
| hsa-miR-21   | hsa-miR-127  | hsa-miR-130a | hsa-miR-22#   |
| hsa-miR-214  | hsa-miR-132  | hsa-miR-195  | hsa-miR-148b  |
| hsa-miR-574-3p | hsa-miR-331 | hsa-miR-411  | hsa-miR-139-5p|
| hsa-miR-193b | hsa-miR-328  | hsa-miR-148a | hsa-miR-505#  |
| hsa-miR-197  | hsa-miR-181a | hsa-miR-126  | hsa-miR-302a  |
| hsa-miR-29a  | hsa-miR-222# | hsa-miR-483-5p | hsa-miR-362 |
| hsa-miR-16   | hsa-miR-1290 | mmu-miR-374-5p | hsa-miR-136# |
| hsa-miR-31   | hsa-miR-224  | hsa-miR-30d  | hsa-miR-128a  |
| hsa-miR-409-3p | hsa-miR-125a-5p | hsa-miR-590-5p | hsa-miR-27a# |
| hsa-miR-30c  | hsa-miR-28-3p | hsa-miR-26b  | hsa-miR-199a  |
| hsa-miR-145  | mmu-miR-140  | hsa-miR-1271 | hsa-miR-655   |
| hsa-miR-145  | rno-miR-7#   | hsa-miR-660  | hsa-miR-885-5p|
| hsa-miR-320  | hsa-miR-27a  | hsa-miR-34b  | hsa-miR-455   |
| hsa-miR-17   | hsa-miR-374  | hsa-miR-20b  | hsa-miR-423-5p|
| hsa-miR-484  | hsa-miR-212  | hsa-miR-196b | hsa-miR-638   |
| hsa-miR-221  | hsa-miR-10a  | hsa-miR-93#  | hsa-miR-889   |
| hsa-miR-30b  | hsa-miR-143  | hsa-miR-339-3p | hsa-miR-204 |
| hsa-miR-199a-3p | hsa-miR-425-5p | hsa-miR-432  | hsa-miR-576-3p|
| hsa-miR-10b  | mmu-miR-93   | hsa-miR-335# | hsa-miR-193a-3p|
| hsa-miR-106a | hsa-miR-34a#  | hsa-miR-494  | hsa-miR-19b-1#|
| hsa-miR-422a | hsa-miR-486  | hsa-miR-296  | hsa-miR-628-3p|
| hsa-miR-138  | hsa-miR-150  | hsa-miR-193b# | hsa-miR-409-5p|
| hsa-miR-657  | hsa-miR-10b#  | mmu-miR-137  | hsa-miR-202   |
| hsa-let-7b   | mmu-miR-134  | hsa-miR-28   | hsa-miR-203   |
| hsa-miR-99b  | hsa-miR-146b | hsa-miR-130b | hsa-miR-572   |
| hsa-miR-886-3p | hsa-miR-193a-5p | hsa-miR-744  | hsa-miR-338-5p|
| hsa-miR-30a-3p | hsa-miR-376a  | hsa-miR-301  |               |
| hsa-miR-30a-5p | hsa-let-7c   | mmu-miR-495  |               |
Table 2 List of the miRNAs selectively detected inside the CF2 fraction

| Selective miRNA in medium-density CF2 EVs |
|-----------------------------------------|
| hsa-miR-107                            |
| hsa-miR-122                            |
| hsa-miR-135b                           |
| hsa-miR-190                            |
| hsa-miR-198                            |
| hsa-miR-199b                           |
| hsa-miR-205                            |
| hsa-miR-211                            |
| hsa-miR-301b                           |
| hsa-miR-302b                           |
| hsa-miR-32                            |
| hsa-miR-331-5p                         |
| hsa-miR-334c                           |
| hsa-miR-369-3p                         |
| hsa-miR-375                            |
| hsa-miR-381                            |
| hsa-miR-383                            |
| hsa-miR-449                            |
| hsa-miR-450a                           |
| hsa-miR-492                            |
| hsa-miR-500                            |
| hsa-miR-502                            |
| hsa-miR-518a-3p                        |
| hsa-miR-542-3p                         |
| hsa-miR-545                            |
| hsa-miR-550                            |
| hsa-miR-570                            |
| hsa-miR-579                            |
| hsa-miR-616                            |
| hsa-miR-95                             |
| hsa-miR-98                             |
| dme-miR-7                             |
| hsa-let-7f-2#                         |
| hsa-let-7 g#                          |
| hsa-miR-106b#                         |
| hsa-miR-1179                          |
| hsa-miR-1201                          |
| hsa-miR-1226#                         |
| hsa-miR-1227                          |
| hsa-miR-1254                          |
| hsa-miR-1270                          |
| hsa-miR-1276                          |
| hsa-miR-1291                          |
| hsa-miR-130b#                         |
| hsa-miR-144#                          |
| hsa-miR-15a#                          |
| hsa-miR-15b#                          |
| hsa-miR-191#                          |
| hsa-miR-206                           |
| hsa-miR-20a#                          |
| hsa-miR-24-1#                         |
| hsa-miR-24-2#                         |
| hsa-miR-25#                           |
| hsa-miR-27b#                          |
| hsa-miR-302d                          |
| hsa-miR-361-3p                        |
| hsa-miR-378                           |
| hsa-miR-380-5p                        |
| hsa-miR-411#                          |
| hsa-miR-550                           |
| hsa-miR-580                           |
| hsa-miR-603                           |
| hsa-miR-744#                          |
| hsa-miR-770-5p                        |
| hsa-miR-941                           |
| hsa-miR-942                           |
| hsa-miR-944                           |
| hsa-miR-99a#                          |

pathway analysis on the CF proteome (413 proteins) found high representation of the following pathways: interleukin mediated signaling, inflammation mediated by chemokine and cytokine, TGF-β signaling, gonadotropin release hormone receptor, angiogenesis and Wnt signaling pathways (Fig. 7b). CFs contained proteins which originate from different cellular compartments such as extracellular region, plasma membrane, extracellular matrix, vesicle lumen and secretory granules (Table 4). Moreover, proteins of the CF proteome were mainly incorporated in the following classes: signaling molecules, receptors, defense/immunity proteins, enzyme modulators and cell adhesion molecules (Fig. 7c). The top ten GO biological processes overrepresented by the CF proteome were mainly associated with regulation of cell proliferation, response to wounding, enzyme linked receptor protein signaling pathway, inflammatory response, receptor linked signal transduction, immune response and regulation of phosphorylation (Fig. 7d).

Differential expression analysis reveals that of the 655 proteins expressed in the medium-density EVs from CF2 fraction, 75 proteins were significantly up-regulated in respect to CF3 and 92 proteins resulted up-regulated in respect to CF1 (Table 5). Of them, 27 were commonly down-regulated in both fractions. Selective proteins were up-regulated in CF1 and CF3 in respect to CF2 fractions (FC CF2 < 0.65) (CF1: TGFBR2 and SFRP1 and CF3: NTRK2, EPHA5, SRMS, LTK, TNFRSF1B, TGFBR1).

To investigate the differences at biological levels among fractions, we performed functional enrichment analyses of the proteins upregulated in CF2 in respect to CF3 and CF1. Enriched GO molecular function (GO-MF) terms overrepresented by the proteins upregulated in CF2 in respect to CF3, were mainly incorporated in: transmembrane receptor and receptor-binding activities, G-protein couple receptor activity, cytokine and hormone activities and cell adhesion molecules (Fig. 8a, outer chart). The GO-MF overrepresented for proteins upregulated in CF2 in respect to the low-density fraction CF1 were largely associated with cell adhesion molecules, receptor binding and activity (Fig. 8a, inner chart). Selective molecular functions were metallopeptidases and protein tyrosine-kinase activity (Fig. 8a, inner chart).

Enriched GO biological processes (GO-BP) of proteins upregulated in CF2 in respect to CF3 were chemotaxis, signal transduction via receptor interaction, cell proliferation, response to wounding, cell-cell signaling, development and inflammation (Fig. 8b). Enriched GO-BP were also observed, for proteins down-regulated in CF1 in respect to CF2. These include common processes such as signal transduction via receptor interaction, cell proliferation, response to wounding and cell-cell signaling. Selective processes such as cell adhesion, regulation of cell differentiation and apoptosis were also detected (Fig. 8c).

Discussion

The results of the present study demonstrated that EVs isolated from the conditioned medium of MSCs, using the gradient separation technique, are heterogeneous in their quantity and composition. Based on the differential expression of specific exosome enriched-markers and different density among the twelve fractions, we grouped them in three combined fractions. The combined fractions, displayed differential pro-proliferative and anti-apoptotic activities on renal tubular epithelial cells. Comparative miRNome and proteomic profiles, revealed a cluster of miRNAs and proteins common to the three vesicle fractions and fraction specific subsets of RNAs and proteins.

EVs have been described as important players of the MSC secretome. In fact, the beneficial effect of MSC treatment on different models of acute and chronic damages was mimic by a vesicles-based therapy [2, 16, 34–36]. EVs are composed of several subpopulations and most of their characteristics are not exclusive of a specific class of EVs [23]. For this reason, the possibility that they act as distinct biological entities is now under evaluation [37].
EVs released by MSCs, were a mixed population with different diameters and with two prominent peaks around 100 and 180 nm, as detected by NTA. EVs isolated by discontinuous density gradient separation showed a heterogeneity in quantity and expression of the classical exosomal markers. The exosomal markers were mainly detected in the medium-density gradient fractions (1.08–1.14 g/mL density) which co-expressed the CD63 with classical mesenchymal vesicular

| KEGG pathway                                      | p-value   | #genes | #miRNAs |
|---------------------------------------------------|-----------|--------|---------|
| Fatty acid biosynthesis                           | <1e-325   | 4      | 5       |
| Fatty acid metabolism                             | <1e-325   | 12     | 7       |
| Glioma                                            | <1e-325   | 40     | 10      |
| Lysine degradation                                 | <1e-325   | 24     | 16      |
| Hippo signaling pathway                            | <1e-325   | 89     | 18      |
| ECM-receptor interaction                          | <1e-325   | 48     | 19      |
| TGF-beta signaling pathway                         | <1e-325   | 59     | 22      |
| Signaling pathways regulating pluripotency of stem cells | <1e-325   | 100   | 24      |
| Proteoglycans in cancer                            | <1e-325   | 128    | 30      |
| Biosynthesis of unsaturated fatty acids            | 8.88E-16  | 9      | 8       |
| Mucin type O-Glycan biosynthesis                   | 8.65E-11  | 17     | 12      |
| Wnt signaling pathway                              | 8.54E-10  | 43     | 5       |
| Prion diseases                                     | 1.99E-09  | 2      | 2       |
| Thyroid hormone signaling pathway                  | 1.56E-08  | 59     | 10      |
| Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 3.91E-07  | 9      | 10      |
| Pathways in cancer                                 | 9.90E-07  | 163    | 10      |
| Estrogen signaling pathway                         | 2.44E-06  | 19     | 6       |
| FoxO signaling pathway                             | 4.67E-06  | 58     | 5       |
| Focal adhesion                                     | 8.59E-06  | 54     | 3       |
| Melanoma                                           | 1.84E-05  | 40     | 8       |
| Amoebiasis                                         | 1.90E-05  | 24     | 4       |
| PI3K-Akt signaling pathway                         | 0.0004    | 74     | 3       |
| Morphine addiction                                 | 0.0005    | 38     | 6       |
| Axon guidance                                      | 0.0015    | 61     | 10      |
| Amphetamine addiction                              | 0.0026    | 26     | 6       |
| Prostate cancer                                    | 0.0031    | 16     | 3       |

**Fig. 6** Heatmap representation of the most significantly enriched pathways potentially modulated by the selective/enriched miRNAs in CF2 fraction. Enrichment analysis of the pathways over-represented by the predicted targets of enriched/selective CF2 miRNAs was conducted using the software DIANA mirPath. miRNAs with similar patterns in targeting significant pathways clustered together (69 miRNAs). Strong correlation with the pathways assembled in metabolic, stem cell associated- and migration/inflammation processes was observed. Only pathways targeted by the selected miRNAs with a P-value < 0.01 (FDR corrected) were considered for the analysis.
markers such as CD29 and ITGA5 [2], and ANXA2 an important effector of miRNA recruitment in EVs [38].

The selective expression of miR-451, in the central fractions of the gradient EVs, further supports the enrichment in exosomes of this fraction, since previous studies in tumor cell lines showed that this miRNA is preferentially sorted into exosomes [39].

According to Xu et al. [40], the denser fractions contained microvesicle-enriched populations. CF3 denser fraction, despite the presence of CD63, does not or barely express the HLA-1 and ITGA5 suggesting that is a different population from CF2. Moreover, CF3 is enriched in EVs of larger size (>200 nm) and showed the highest mean diameter among the different EV populations, supporting the enrichment in microvesicles of this fraction. The low-density CF1 fraction contained an undefined population of EVs, that expressed low levels of CD29 and ANXA2 and were negative for all the other markers tested.

Xu et al. demonstrated that exosomes and microvesicles isolated by differential centrifugation from human colon cancer cells, have distinct biological activities, being able to promote invasiveness at different rating [40]. Moreover, Aliotta et al. showed that exosomes-enriched and microvesicle-enriched populations from mouse MSCs, have different effects when infused into mice, in a model of monocrotaline induced pulmonary hypertension [41]. The same biological
differences in mouse and human MSC EVs sub-populations were demonstrated by Wen et al., using a model of marrow radiation damage [42]. We previously showed the ability of MSC EVs, to promote proliferation and to protect from apoptosis murine and human renal epithelial tubular cells [2, 43]. These effects were ascribed to a heterogeneous population of EVs containing both microvesicles and exosomes. We here demonstrated that different EV fractions separated by discontinuous iodixanol gradient based on their density, display differential pro-proliferative and anti-apoptotic activities on recipient renal tubular cells despite they were equally internalized by mTEC. EVs from CF1 and CF2 low and medium-density fractions induced proliferation on renal tubular cells, cultured in the absence of serum. However, the CF2 enriched-exosome population was more effective than the others combined fractions in the protection from apoptosis induced by hypoxia/reperfusion injury on renal target cells. High-density EVs in fraction CF3, conceivable containing a microvesicle-enriched population, did not induce significant protection from apoptosis and proliferation of renal tubular cells, also after enhancing the dose of EVs administered.

The activity of EVs has been at least in part ascribed to their miRNA content [42–45]. A subset of miRNA families, was specific signature of the biologically active CF2 medium-density fraction. Some of these miRNAs, such as miR-17-5p and miR-106a have been described together with miR-21 as differentially expressed during different phases of renal injury, being potential biomarkers for AKI [32]. Interestingly, different miRNA* sequences were only detected in CF2 fraction, supporting the potential of exosomes to transfer miRNA* outside the cells [14].

Several other miRNAs enriched in CF2 fraction, were reported as protective in the context of AKI including miR-34 [27], miR-125b [31], miR-199a-3p, miR-214 [28] and miR-127 [29]. miR-21 and miR-29, enhanced in CF2, have been linked to the modulation of kidney fibrosis [30]. miR-451 selectively present in the central fractions of the gradient, has been demonstrated to act together with miR-144, in the protection against IRI in the heart [46]. All the miRNAs analyzed were reduced in the CF1, supporting a less enrichment of miRNAs in this fraction.

Enrichment analysis of the pathways over-represented by the predicted targets of enriched/selective CF2 miRNAs showed strong correlation with metabolic, stem cell associated- and migration/inflammation processes. High representation of fatty acid biosynthesis and metabolism, Wnt signaling and pluripotent stem cells regulated-pathways, ECM-receptor interaction and TGF-β signaling pathway have been detected. Interestingly, downregulation of fatty acid oxidation in tubular cells has been described as a key component of the pathogenesis of AKI [47]. Moreover, stem cell and Wnt/β-catenin signaling pathways have been also correlated with repair processes after ischemic AKI [48].

Proteins are together with RNA, important effectors for the EV activity. By protein array, we identified a protein cargo of 413 proteins detected in all the different EV fractions. Cross match with Vesiclepedia database [49] identified 205 classical EV proteins detected in all the EV fractions. Proteins of the CF proteome were mainly incorporated as signaling molecules, receptors and cell adhesion molecules, recently connected with the potential therapeutic effects of the microvesicles from MSCs [50]. Defense/immunity proteins and enzyme

| GO Term | Count | % | PValue | Bonferroni | FDR |
|---------|-------|---|--------|------------|-----|
| GO:0005615 ~ extracellular space | 150 | 38.66 | 4.03E-94 | 1.04E-91 | 5.26E-91 |
| GO:0044421 ~ extracellular region part | 167 | 43.04 | 1.11E-89 | 2.85E-87 | 1.45E-86 |
| GO:0005576 ~ extracellular region | 226 | 58.25 | 4.14E-89 | 1.06E-86 | 5.40E-86 |
| GO:0031226 ~ intrinsic to plasma membrane | 92 | 23.71 | 5.60E-18 | 1.44E-15 | 7.31E-15 |
| GO:0005887 ~ integral to plasma membrane | 90 | 23.20 | 1.41E-17 | 3.63E-15 | 1.84E-14 |
| GO:0009986 ~ cell surface | 43 | 11.08 | 3.29E-15 | 8.56E-13 | 4.34E-12 |
| GO:0004459 ~ plasma membrane part | 116 | 29.90 | 3.79E-11 | 9.75E-09 | 4.95E-08 |
| GO:0009897 ~ external side of plasma membrane | 24 | 6.19 | 7.76E-10 | 2.00E-07 | 1.01E-06 |
| GO:0043235 ~ receptor complex | 19 | 4.90 | 6.19E-09 | 1.59E-06 | 8.08E-06 |
| GO:0031012 ~ extracellular matrix | 31 | 7.99 | 8.64E-08 | 2.22E-05 | 1.13E-04 |
| GO:0060205 ~ cytoplasmic membrane-bounded vesicle lumen | 11 | 2.84 | 3.96E-07 | 1.02E-04 | 5.17E-04 |
| GO:0031983 ~ vesicle lumen | 11 | 2.84 | 6.18E-07 | 1.59E-04 | 8.07E-04 |
| GO:0031093 ~ platelet alpha granule lumen | 10 | 2.58 | 2.09E-06 | 5.37E-04 | 0.002 |
| GO:0005578 ~ proteinaceous extracellular matrix | 27 | 6.96 | 2.32E-06 | 5.97E-04 | 0.003 |
| GO:0005886 ~ plasma membrane | 152 | 39.18 | 2.62E-06 | 6.74E-04 | 0.003 |
| GO:0031091 ~ platelet alpha granule | 11 | 2.84 | 4.17E-06 | 0.001 | 0.005 |
| GO:0030141 ~ secretory granule | 19 | 4.90 | 5.13E-06 | 0.001 | 0.006 |
modulators class of proteins were also detected in the CF proteome. Moreover, they were classified as extracellular, plasma membrane, matrix and vesicle proteins. Pathway analysis of the CF proteome reveals high representation of pathways such as interleukin mediated signaling and chemokine/cytokine mediated inflammation, Wnt signaling, TGF-β and angiogenesis pathways. MSC CF proteome was relevantly enriched in anti- and pro-inflammatory cytokines.

Moreover, EVs from all CF fractions expressed the chemokines receptors of cell of origin, such as CXCR1, CXCR6, CXCR4, CXCR3, CCR3 and CCR7, known to be involved in the migration to the sites of inflammation [51]. Eph A4 and different subclasses of the Eph B receptors, regulators of MSC attachment/migration [52] and inhibitors of T cell proliferation [53], were also present in all EV fractions. Moreover, numerous pro-angiogenic and pro-migratory molecules such as the soluble factors VEGF, TGF-β, IL-8 and PDGF and PDGFRα/β were compartmentalized in all the CF fractions. Interestingly, increasing angiogenesis together with renal blood flow have been recently observed in IRI rats treated with adipose mesenchymal stem cell exosomes and associated with the reversion of the kidney damage [54].

The catalytic subunit PI3-Kinase p85-beta, detected among the 50 major expressed proteins of CF proteome, has been

### Table 5

| List of proteins over-expressed in CF2 (FC CF2 > 1.5) |
|------------------------------------------------------|
| TIMP2 Thymidine Kinase1 | BDNF | CCL11 | IL1 F6 |
| ALK4 SPINK1 | Frizzled6 | VEGF R3 | Activin B |
| MCSF R ALCAM | PGF | 11bHSD1 | betaCatenin |
| hCG alpha CTGF | IL17RC | TSLP R | TNFRSF12 |
| FGFBP IL3 R alpha | HGF | Neurophin2 | GPNMB |
| ACTH Tryptsin 1 | IGFI | FGF R4 | IL1 R3 |
| PAI1 OSM | CCR8 | VWF | CXCL16 |
| VEGFC CXCR3 | CCR6 | S100A6 | Leptin (OB) |
| IL21 R ENA78 | IGFBP1 | S100A10 | CCR1 |
| RAGE MCSF | TNFRSF1A | TNFRSF11B | IFNalpha / beta R1 |
| Resistin IL17R | CD56 | IL28A | LRP6 |
| GDNF CXCR2 | IL12 p40 | Tissue Factor | DANCE |
| Thrombospondin4 TFPI | proGlucagon | Gastrin | NeuroD1 |
| PLUNC CCR5 | Chem R23 | BMP2 | CCR2 |
| FGF R3 TOPORS | NT4 | TNFSF8 | ApoE3 |

| List of proteins over-expressed in CF2 in respect to CF1 |
|------------------------------------------------------|
| Thrombospondin1 Plasminogen | ICAM5 | SRMS | IL15 R alpha |
| Fibronectin hCG alpha | NeurokininA | BCAM | BMP2 |
| ApoA4 PTHLP | CD14 | CCR6 | TNFSF8 |
| Factor XIII A CNDP1 | ALCAM | CCL16 | Activin B |
| Clusterin APC | CKMB | CD56 | betaCatenin |
| TYRO10 FGFBP | HADHA | HBEGF | IL1 R3 |
| ACK1 CA 153 | TNFRSF17 | proGlucagon | ICAM2 |
| ALPP ACTH | TNFRSF5 | MMP25 | LRP6 |
| Ubiquitin + 1 PAI1 | CCR5 | ErbB2 | DANCE |
| Btk Cardiotrophin1 | Frizzled5 | CCL11 | NeuroD1 |
| TNFRSF21 VEGFC | BDNF | Protein p65 | IL17C |
| BAI1 TRKB | APJ | FAP | FGF9 |
| Activin A CEA | IFNgamma R1 | HSP10 | CCR2 |
| SERPINA6 CBP | ApoC1 | CD80 | GLO1 |
| Beta IGH3 IGFBP7 | CD117 | TNFSF3 | PDX1 |
| CA 125 Calcitonin | IGFI | ErbB3 | ApoE3 |
| ABL1 AR | IL29 | EGF | |
| TIMP2 Thymidine Kinase1 | CCR8 | Apelin | |
| ALK4 C9 | IL1 F5 | ADAMTS10 | |
recently correlated with cell cycle re-entry and proliferation via PI3K/Akt signaling pathway activation [55].

The protein associated biological processes overrepresented in CF2, which was the most biologically active fraction, included positive regulators of proliferation, response to wounding and cell-cell signaling possibly accounting for the pro-proliferative activity of CF EVs. Migration/proliferation processes were also over-represented by the enriched miRNAs in the medium-density CF2 fraction, showing a collaborative pattern of proteins and miRNAs shuttled by MSCs in promoting regenerative processes. Interestingly, TGF-β pathway crucial in AKI progression to chronic kidney disease [56] was overrepresented both by miRNAs and proteins compartmentalized in the CF2 fraction, suggesting the regulation of this pathway by MSC EVs treatment.

Of interest, the major cytokine enriched in CF2 fraction was the IL-13 that together with IL-10 and IL-4, mediates differentiation of monocytes in non-inflammatory (M2) macrophages [57]. Recently, MSCs have shown the ability to educate macrophages to acquire an anti-inflammatory M2 phenotype, promoting kidney repair in rhabdomyolysis-induced acute kidney injury [58]. Further, CF2 EVs contained high levels of ApoC3 and ApoA4, recently detected inside the EVs produced by umbilical cord blood-derived MSCs with other family members and involved in inflammation and tissue repair [59].

In conclusion, this study demonstrated that EVs derived from MSCs are heterogeneous with specific signatures accounting for the biological activity of different EV populations. Proteins and miRNAs shuttled by MSCs showed a collaborative pattern in crucial processes activated after injury, such as metabolic, stem cell, inflammation/migration and angiogenic related processes. Moreover, the medium-density CF2 fraction containing exosome-enriched population of EVs showed the best activity in promoting renal protection from injury in vitro. This fraction was enriched in miRNAs...
and proteins associated with biological processes fundamental in kidney regeneration.

Acknowledgements This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) and National Center For Advancing Translational Sciences of the National Institutes of Health under Award number UH2TR000880, UH3TR000880-03S1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with Ethical Standards

Disclosures The authors indicate no potential conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Ratajczak, J., Miekus, K., Kucia, M., et al. (2006). Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia, 20(5), 847–856.
2. Bruno, S., Grange, C., Deregibus, M. C., et al. (2009). Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. Journal of the American Society of Nephrology, 20(5), 1053–1067.
3. Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S. K., & Ho, H. K. (2014). Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Research & Therapy, 5(3), 76–89.
4. Zhu, Y. J., Sun, J., & Du, T. (2015). Microvesicles derived from human umbilical cord mesenchymal stem cells facilitate tubular epithelial cell dedifferentiation and growth via hepatocyte growth factor induction. PLoS One, 10(3), e0121534.
5. Nakamura, Y., Miyaki, S., Ishibashi, H., et al. (2015). Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration. FEBS Letters, 589(11), 1257–1265.
6. Deregibus, M. C., Cantaluppi, V., Calogero, R., et al. (2007). Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood, 110(7), 2440–2448.
7. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9(6), 654–659.
8. Collino, F., Deregibus, M. C., Bruno, S., et al. (2010). Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One, 5(7), e11803.
9. Lai, R. C., Tan, S. S., Teh, B. J., et al. (2012). Proteolytic potential of the MSCS exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. The International Journal of Prosthodontics. doi:10.1155/2012/971907.
10. Nolte-'t Hoen, E.N., Buermans, H.P., Waasdorp, M., Stoorvogel, W., Wauben, M.H., 't Hoen, P.A. (2012) Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Research, 40(18), 9272–9285.
11. Konala, V. B., Mamidi, M. K., Bhonde, R., Das, A. K., Pochampally, R., & Pal, R. (2016). The current landscape of the mesenchymal stromal cell secretome: a new paradigm for cell-free regeneration. Cytotherapy, 18(1), 13–24.
12. Chiassirini, D., Mazzoni, M., Bordi, F., et al. (2015). Identification and partial characterization of two populations of Prostasomes by a combination of dynamic light scattering and proteomic analysis. The Journal of Membrane Biology, 248(6), 991–1004.
13. Guduric-Fuchs, J., O’Connor, A., Camp, B., O’Neill, C. L., Medina, R. J., & Simpson, D. A. (2012). Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics, 13, 357. doi:10.1186/1471-2164-13-357.
14. Ji, H., Chen, M., Greening, D. W., et al. (2014). Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures. PLoS One, 9(10), e110314.
15. Lenassi, M., Cagney, G., Liao, M., et al. (2010). HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic, 11(1), 110–122.
16. Lai, R. C., Arslan, F., Lee, M. M., et al. (2010). Exosome secreted from MSCs reduces myocardial ischemia/reperfusion injury. Stem Cell Research, 4(3), 214–222.
17. Greening, D. W., Xu, R., Ji, H., Tauro, B. J., & Simpson, R. J. (2015). A protocol for exosome isolation and characterization: evaluation of ultra centrifugation, density-gradient separation, and immunoaffinity capture methods. Methods in Molecular Biology, 1295, 179–209.
18. Taylor, D. D. (2015). Isolation and molecular characterization of extracellular vesicles. Methods, 87, 1–2. doi:10.1016/j.ymeth.2015.08.006.
19. Tomasoni, S., Longaretti, L., Rota, C., et al. (2013). Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells and Development, 22(5), 772–780.
20. Collino, F., Bruno, S., Incarnato, D., et al. (2015). AKI recovery induced by mesenchymal stromal cell-derived extracellular vesicles carrying MicroRNAs. Journal of the American Society of Nephrology, 26(10), 2349–2360.
21. Herrera, M. B., Fonsato, V., Bruno, S., et al. (2013). Human liver stem cells improve liver injury in a model of fulminant liver failure. Hepatology, 57(1), 311–319.
22. Tauro, B. J., Greening, D. W., Mathias, R. A., et al. (2012). Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods, 56(2), 293–304.
23. Kowal, J., Arras, G., Colombo, M., et al. (2016). Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proceedings of the National Academy of Sciences of the United States of America, 113(8), E968–E977.
24. Mestdagh, P., Van Vlierberghe, P., De Weer, A., et al. (2009). A novel and universal method for microRNA RT-qPCR data normalization. Genome Biology, 10(6), R64. doi:10.1186/gb-2009-10-6-r64.
25. Vlachos, I. S., Zagganas, K., Paraskevopoulou, M. D., et al. (2015). DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Research, 43(W1), W460–W466.
26. Pathan, M., Keerthikumar, S., Ang, C. S., et al. (2015). FunRich: a standalone tool for functional enrichment analysis. Proteomics, 15, 2597–2601.
